论文部分内容阅读
目的:18F-FES作为雌激素受体特异性的显影剂,可反映乳腺癌组织雌激素表达水平。本次研究主要探讨病理免疫组化与18F-FES在乳腺癌患者体内摄取的相关性。方法:选取我院2014年3月至2015年3月符合入选标准的乳腺癌患者20例作为研究对象,所有患者行18FFES PET-CT及病理穿刺活检。比较18F-FES PET-CT及病理穿刺活检检查结果的差异性及一致性。结果:18F-FES PET-CT的灵敏度为95%,特异度为95%。结论:病理免疫组化与18F-FES在乳腺癌患者具有很高的相关性,可为临床治疗提供指导价值。
OBJECTIVE: 18F-FES, as a estrogen receptor-specific imaging agent, can reflect the expression of estrogen in breast cancer tissues. This study focused on the relationship between pathological immunohistochemistry and 18F-FES uptake in breast cancer patients. METHODS: Twenty patients with breast cancer who met the inclusion criteria from March 2014 to March 2015 in our hospital were selected as study subjects. All patients underwent 18F PET-CT and pathological biopsy. The difference and consistency of 18F-FES PET-CT and pathological biopsy were compared. Results: The sensitivity and specificity of 18F-FES PET-CT were 95% and 95% respectively. Conclusion: There is a high correlation between pathological immunohistochemistry and 18F-FES in breast cancer patients, which may provide guidance for clinical treatment.